Astellas Pharma Q1 2025 Earnings Report $9.68 -0.21 (-2.12%) As of 01/31/2025 03:59 PM Eastern Earnings History Astellas Pharma EPS ResultsActual EPS$0.24Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAstellas Pharma Revenue ResultsActual Revenue$3.03 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAstellas Pharma Announcement DetailsQuarterQ1 2025Date8/1/2024TimeN/AConference Call ResourcesALPMY Earnings History Astellas Pharma Earnings HeadlinesJefferies Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)January 25, 2025 | markets.businessinsider.comFDA Accepts Astellas Pharma's Revised SNDA For IZERVAY In Geographic Atrophy TreatmentJanuary 9, 2025 | markets.businessinsider.comElon’s Chosen OnesMillions of Federal employees just got put on notice... In a single sweeping move, President Trump just offered to pay eight months' salary to any Federal worker who voluntarily quits. But according to one Boston-based think tank, who has consulted with the Pentagon, US Army, Harvard and who's work has been followed by many of the world's biggest banks...February 1, 2025 | Altimetry (Ad)Astellas Pharma : China's NMPA Approves VYLOY For Advanced Gastric/Gastroesophageal Junction CancerJanuary 5, 2025 | markets.businessinsider.comAxcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein DegradersDecember 25, 2024 | businesswire.comAstellas and Sangamo sign capsid deal for neurological diseasesDecember 20, 2024 | msn.comSee More Astellas Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email. Email Address About Astellas PharmaAstellas Pharma (OTCMKTS:ALPMY) manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.View Astellas Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings PayPal (2/3/2025)Palantir Technologies (2/3/2025)NXP Semiconductors (2/3/2025)Mitsubishi UFJ Financial Group (2/3/2025)Mondelez International (2/4/2025)Advanced Micro Devices (2/4/2025)Alphabet (2/4/2025)Alphabet (2/4/2025)Amgen (2/4/2025)Banco Bilbao Vizcaya Argentaria (2/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
